Moreover, molecular profiling of these two proteins in pretreated and resistant tumor samples will help to elucidate if the loss of KEAP1 or the gain of NFE2L2 may be clinically relevant mechanisms of acquired and intrinsic resistance to therapies in lung cancer and other solid tumors or not. The gene discussed is KEAP1; the disease is neoplasm.